Ipsen Reports Half-Year Financial Performance for 2025
Half-Year Financial Summary of Ipsen
Overview
As of June 30, 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has provided an update on its liquidity agreement facilitated by NATIXIS ODDO BHF. During this period, significant transactions have taken place in the dedicated liquidity account.
Liquidity Account Activity
The recent report reveals that the liquidity resources included in the dedicated account accounted for:
• 38,030 shares
• €1,320,416.64
At the inception of the liquidity agreement, the account had assets totaling:
• 12,751 shares
• €3,137,934.80
Transaction Highlights
From January 1 to June 30, 2025, there were notable trading activities with the following executed transactions:
• 2,468 purchase transactions
• 2,393 sell transactions
The total volume traded during this time comprised:
• 339,729 shares and €36,644,907.65 for purchases
• 326,400 shares and €35,329,344.25 for sales
About Ipsen
Ipsen is a leading global biopharmaceutical company dedicated to transforming patient care across three core therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Our innovative pipeline is significantly driven by external collaborations and boasts nearly a century of expertise in development.
With a presence in over 40 countries, Ipsen leverages partnerships worldwide to deliver advanced medical solutions to patients in more than 80 nations. The company is publicly traded on Euronext under the ticker symbol IPN and offers a Sponsored Level I American Depositary Receipt (ADR: IPSEY) in the U.S.
Contact Information
Investors Contact:
Khalid Deojee - khalid.deojee@ipsen.com - + 33 6 66 01 95 26
Media Inquiries (Global):
Sally Bain - sally.bain@ipsen.com - + 1 857 320 0517
Media Inquiries (Local):
Anne Liontas - anne.liontas.ext@ipsen.com - + 33 7 67 34 72 96
Frequently Asked Questions
What is the recent financial performance of Ipsen?
Ipsen's half-year statement highlighted significant liquidity resources with notable share trading activity, including over 2,000 transactions.
What therapeutic areas does Ipsen focus on?
Ipsen's primary focus areas are Oncology, Rare Diseases, and Neuroscience, reflecting its commitment to crucial medical sectors.
How does Ipsen support its pipeline innovations?
The company fosters innovation through external collaborations and boasts nearly 100 years of development expertise in the biopharmaceutical field.
Where is Ipsen traded?
Ipsen is listed on Euronext under the ticker IPN and has a Sponsored Level I ADR in the U.S. under the ticker IPSEY.
Who can I contact for more information about Ipsen?
For investor relations, you can contact Khalid Deojee at khalid.deojee@ipsen.com. For media inquiries, reach out to Sally Bain or Anne Liontas based on your region.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.